Schillinger, Wolfgang

[["dc.bibliographiccitation.firstpage","286"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","EuroIntervention"],["dc.bibliographiccitation.lastpage","293"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Puls, Miriam"],["dc.contributor.author","Korte, Kerstin Pia"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Huenlich, Mark"],["dc.contributor.author","Danner, Bernhard"],["dc.contributor.author","Schoendube, Friedrich"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Jacobshagen, Claudius"],["dc.contributor.author","Schillinger, Wolfgang"],["dc.date.accessioned","2021-06-01T10:48:55Z"],["dc.date.available","2021-06-01T10:48:55Z"],["dc.date.issued","2017"],["dc.description.abstract","AIMS: The objective of this study was to examine the impact of guideline-defined subtypes of severe aortic stenosis (AS) on long-term outcomes after TAVI. METHODS AND RESULTS: Four hundred (400) consecutive patients who underwent TAVI (203 transapical, 197 transfemoral) at our institution 8/2008-3/2013 were followed systematically (for up to seven years). One hundred and forty-seven (147) individuals suffered from NEF-HG AS (LV-EF ≥50%, high Pmean ≥40 mmHg), 63 from LEF-HG AS (LV-EF <50%, high gradient), 77 from PLF-LG AS (LV-EF ≥50%, low gradient, stroke volume index [SVI] <35 ml/m²), and 81 from LEF-LG AS (LV-EF <50%, low gradient). LEF-LG status was associated with the highest all-cause and cardiovascular mortality and MACCE rate, whereas NEF-HG patients exhibited the best outcome (i.e., median survival 5.1 years in NEF-HG vs. 1.3 years in LEF-LG, p=0.0006; or vs. 3.3 years in PLF-LG, p=0.02). In multivariate analysis, LEF-LG status emerged as the outcome predictor with the highest hazard ratio for all-cause mortality (HR 2.86, p=0.003), cardiovascular mortality (HR 6.53, p<0.0001), and MACCE (HR 2.44, p=0.007), whereas neither baseline EF nor SVI <35 ml/m² independently predicted these endpoints. CONCLUSIONS: These findings suggest that an assessment of LV-EF alone for outcome prediction after TAVI is inadequate; it is the guideline-defined subtype of AS that determines outcome."],["dc.identifier.doi","10.4244/EIJ-D-16-00801"],["dc.identifier.gro","3142338"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86102"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.notes.status","final"],["dc.relation.issn","1774-024X"],["dc.title","Long-term outcomes after TAVI in patients with different types of aortic stenosis: the conundrum of low flow, low gradient and low ejection fraction"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","107"],["dc.bibliographiccitation.journal","International Journal of Cardiology"],["dc.bibliographiccitation.lastpage","111"],["dc.bibliographiccitation.volume","220"],["dc.contributor.author","Tichelbäcker, Tobias"],["dc.contributor.author","Puls, Miriam"],["dc.contributor.author","Jacobshagen, Claudius"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Schillinger, Wolfgang"],["dc.contributor.author","Huenlich, Mark"],["dc.contributor.author","Schroeter, Marco Robin"],["dc.date.accessioned","2017-09-07T11:44:37Z"],["dc.date.available","2017-09-07T11:44:37Z"],["dc.date.issued","2016"],["dc.description.abstract","Background: Percutaneous mitral valve repair using MitraClip (R) (MC) is a well-established method for a subset of patients with severe mitral regurgitation (MR) and high risk for surgical intervention. Amplatzer (R) Cardiac Plug (ACP) occludes left atrial appendage and allows the discontinuation of oral anticoagulation and prevention of thromboembolic stroke. Due to the need for femoral and transseptal access in both procedures, a single approach could lead to minor risk of further complications and shorter cumulative intervention time. Methods: We systematically analysed all four patients who underwent a combined procedure with MC and ACP in our heart-centre. All procedures were performed under fluoroscopic as well as echocardiographic guidance, and follow-up controls in a midterm period were carried out. Results: In all patients (2 male/female; age 73-88 years), MC (1-2 Clips) and ACP (size 18-28mm) were successfully implanted in one procedure (mean total time: 114 +/- 17 min). At least moderate MR was achieved and two patients had no complications and therefore were discharged early. In a third patient, a dislocation of ACP occurred 2 h after the implantation. The oldest patient developed a respiratory insufficiency due to cardiac decompensation and further complications. Conclusion: A combination of MC and ACP in a single procedure was feasible in this first case series of patients without a significant extension of procedure time. However, it might be important to select patients carefully. The location of optimal transseptal puncture may be challenging in regard to ACP placement, even in experienced hands and subsequent complications can occur. (C) 2016 Elsevier Ireland Ltd. All rights reserved."],["dc.identifier.doi","10.1016/j.ijcard.2016.06.170"],["dc.identifier.gro","3141615"],["dc.identifier.isi","000381582000019"],["dc.identifier.pmid","27389439"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/1456"],["dc.notes.intern","WoS Import 2017-03-10 / Funder: Abbott Vascular; St. Jude Medical"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Elsevier Ireland Ltd"],["dc.relation.eissn","1874-1754"],["dc.relation.issn","0167-5273"],["dc.title","MitraClip (R) and Amplatzer (R) cardiac plug implantation in a single procedure: A reasonable approach?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","285"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Clinical Research in Cardiology"],["dc.bibliographiccitation.lastpage","290"],["dc.bibliographiccitation.volume","103"],["dc.contributor.author","Schroeter, M. R."],["dc.contributor.author","Danner, Bernhard Christoph"],["dc.contributor.author","Huenlich, Mark"],["dc.contributor.author","Schillinger, Wolfgang"],["dc.date.accessioned","2018-11-07T09:42:05Z"],["dc.date.available","2018-11-07T09:42:05Z"],["dc.date.issued","2014"],["dc.description.abstract","Aims Percutaneous left atrial appendage closure with Amplatzer(A (R)) Cardiac Plug (St. Jude Medical Inc.) for the prevention of stroke in patients with atrial fibrillation is rapidly propagating. We sought to provide additional safety data. We have screened our database of patients having been treated with Amplatzer(A (R)) Cardiac Plug and found 3 cases with uncommon complications that have not been reported previously. One patient experienced an embolisation of the occluder about 12 months after implantation that potentially resulted from mismatch of occluder size and landing zone. Another patient developed cardiac tamponade 9 days after implantation. This case of delayed effusion was probably not a result of interventional trauma, but might have been provoked by scratching of the inner pericardial membrane. A third patient developed a large thrombus in the left atrium which was considered to be caused by injury of the endothelial wall during implantation. The first two cases could be treated by a percutaneous procedure, the last case by cardiac surgery without any sequelae. Complications after left atrial appendage closure not related to a device-related thrombus can occur later after implantation. With appropriate percutaneous or surgical management these complications can be handled without sequelae."],["dc.identifier.doi","10.1007/s00392-013-0648-0"],["dc.identifier.isi","000333130600004"],["dc.identifier.pmid","24310111"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33876"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Heidelberg"],["dc.relation.issn","1861-0692"],["dc.relation.issn","1861-0684"],["dc.title","Uncommon delayed and late complications after percutaneous left atrial appendage closure with Amplatzer(A (R)) Cardiac Plug"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Der Internist"],["dc.bibliographiccitation.volume","57"],["dc.contributor.author","Puls, Miriam"],["dc.contributor.author","Sobisiak, Bettina"],["dc.contributor.author","von der Ehe, Katrin"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Huenlich, Mark"],["dc.contributor.author","Jacobshagen, Claudius"],["dc.contributor.author","Schillinger, Wolfgang"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.date.accessioned","2018-11-07T10:15:53Z"],["dc.date.available","2018-11-07T10:15:53Z"],["dc.date.issued","2016"],["dc.format.extent","S14"],["dc.identifier.isi","000375417500022"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40912"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","New york"],["dc.relation.issn","1432-1289"],["dc.relation.issn","0020-9554"],["dc.title","The demographic Change requires Innovations- Appropriate Patient Selection for catheter supported Heart Valve Interventions in multi morbid Patient Cohort with high Average Age"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","European Heart Journal"],["dc.bibliographiccitation.volume","33"],["dc.contributor.author","Schillinger, Wolfgang"],["dc.contributor.author","Tichelbaecker, Tobias"],["dc.contributor.author","Huenlich, Mark"],["dc.contributor.author","Puls, Miriam"],["dc.contributor.author","Rueter, Karin"],["dc.contributor.author","Seipelt, Ralf G."],["dc.contributor.author","Hasenfuß, Gerd"],["dc.date.accessioned","2018-11-07T09:07:30Z"],["dc.date.available","2018-11-07T09:07:30Z"],["dc.date.issued","2012"],["dc.format.extent","974"],["dc.identifier.isi","000308012407112"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/25810"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press"],["dc.publisher.place","Oxford"],["dc.relation.eventlocation","Munchen, GERMANY"],["dc.relation.issn","0195-668X"],["dc.title","Determinants for survival and hospitalisation because of congestive heart failure after percutaneous mitral valve repair"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1407"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","EuroIntervention"],["dc.bibliographiccitation.lastpage","1417"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Puls, Miriam"],["dc.contributor.author","Tichelbäcker, Tobias"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Huenlich, Mark"],["dc.contributor.author","von der Ehe, Katrin"],["dc.contributor.author","Beuthner, Bo Eric"],["dc.contributor.author","Rueter, Karin"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Seipelt, Ralf"],["dc.contributor.author","Schoendube, Friedrich"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Schillinger, Wolfgang"],["dc.date.accessioned","2017-09-07T11:46:19Z"],["dc.date.available","2017-09-07T11:46:19Z"],["dc.date.issued","2014"],["dc.description.abstract","Aims: MitraClip implantation is evolving as a potential alternative treatment to conventional surgery in high-risk patients with significant mitral regurgitation (MR). However, outcome predictors are under-investigated. The aim of this study was to identify predictors of midterm mortality and heart failure rehospitalisation after percutaneous mitral valve repair with MitraClip. Methods and results: A total of 150 consecutive patients were followed for a median of 463 days. Survival analyses were performed for baseline characteristics, risk scores and failure of acute procedural success (APS) defined as persisting MR grade 3+ or 4+. Univariate significant risk stratifiers were tested in multivariate analyses using a Cox proportional hazards model. Overall survival was 96% at 30 days, 79.5% at 12 months, and 62% at two years. Multivariate analysis identified APS failure (HR 2.13, p=0.02), NYHA Class IV at baseline (HR 2.11, p=0.01) and STS score >= 12 (HR 2.20, p<0.0001) as significant independent predictors of all-cause mortality, and APS failure (HR 2.31, p=0.01) and NYHA Class IV at baseline (HR 1.89, p=0.03) as significant independent predictors of heart failure rehospitalisation. Furthermore, a post-procedural significant decrease in hospitalisation rate could only be observed after successful interventions (0.89 +/- 1.07 per year before vs. 0.54 +/- 0.96 after implantation, p=0.01). Patients with severely dilated and overloaded ventricles who did not meet EVEREST II eligibility criteria were at higher risk of APS failure. Conclusions: The failure of acute procedural success proved to have the most important impact on outcome after MitraClip implantation."],["dc.identifier.doi","10.4244/EIJV9I12A238"],["dc.identifier.gro","3142144"],["dc.identifier.isi","000337011100009"],["dc.identifier.pmid","24972141"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/5033"],["dc.notes.intern","WoS Import 2017-03-10 / Funder: Abbott Vascular"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Europa Edition"],["dc.relation.eissn","1969-6213"],["dc.relation.issn","1774-024X"],["dc.title","Failure of acute procedural success predicts adverse outcome after percutaneous edge-to-edge mitral valve repair with MitraClip"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","7973165"],["dc.bibliographiccitation.journal","BioMed Research International"],["dc.bibliographiccitation.volume","2018"],["dc.contributor.author","Hünlich, Mark"],["dc.contributor.author","Lubos, Edith"],["dc.contributor.author","Beuthner, Bo Eric"],["dc.contributor.author","Puls, Miriam"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Tichelbäcker, Tobias"],["dc.contributor.author","Rudolph, Volker"],["dc.contributor.author","Baldus, Stephan"],["dc.contributor.author","Schäfer, Ulrich"],["dc.contributor.author","Treede, Hendrik"],["dc.contributor.author","Bardeleben, Ralph Stephan von"],["dc.contributor.author","Blankenberg, Stefan"],["dc.contributor.author","Schillinger, Wolfgang"],["dc.date.accessioned","2020-03-27T08:24:13Z"],["dc.date.available","2020-03-27T08:24:13Z"],["dc.date.issued","2018"],["dc.description.abstract","Positive results of MitraClip in terms of improvement in clinical and left ventricular parameters have been described in detail. However, long-term effects on secondary pulmonary hypertension were not investigated in a larger patient cohort to date. 70 patients with severe mitral regurgitation, additional pulmonary hypertension, and right heart failure as a result of left heart disease were treated in the heart centers Hamburg and Göttingen. Immediately after successful MitraClip implantation, a reduction of the RVOT diameter from 3.52 cm to 3.44 cm was observed reaching a statistically significant value of 3.39 cm after 12 months. In contrast, there was a significant reduction in the velocity of the tricuspid regurgitation (TR) from 4.17 m/s to 3.11 m/s, the gradient of the TR from 48.5 mmHg to 39.3 mmHg, and the systolic pulmonary artery pressure (PAPsyst) from 58.6 mmHg to 50.0 mmHg. This decline continued in the following months (Vmax TR 3.09 m/s, peak TR 38.6 mmHg, and PAPsyst 47.4 mmHg). The tricuspid annular plane systolic excursion (TAPSE) increased from 16.5 mm to 18.9 mm after 12 months. MitraClip implantation improves pulmonary artery pressure, tricuspid regurgitation, and TAPSE after 12 months. At the same time, there is a decrease in the RVOT diameter without significant changes in other right ventricular and right atrial dimensions."],["dc.identifier.doi","10.1155/2018/6817832"],["dc.identifier.pmid","29725600"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/63379"],["dc.language.iso","en"],["dc.relation.eissn","2314-6141"],["dc.relation.issn","2314-6133"],["dc.title","Acute and Long-Term Hemodynamic Effects of MitraClip Implantation on a Preexisting Secondary Right Heart Failure"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","945"],["dc.bibliographiccitation.journal","European Heart Journal"],["dc.bibliographiccitation.lastpage","946"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Kalbacher, D."],["dc.contributor.author","Tigges, E."],["dc.contributor.author","Puls, Miriam"],["dc.contributor.author","Huenlich, Mark"],["dc.contributor.author","Thomas, Christoph"],["dc.contributor.author","Reichenspurner, Hermann"],["dc.contributor.author","Blankenberg, Stefan"],["dc.contributor.author","Schaefer, U."],["dc.contributor.author","Schillinger, Wolfgang"],["dc.contributor.author","Lubos, Edith"],["dc.date.accessioned","2018-11-07T10:10:30Z"],["dc.date.available","2018-11-07T10:10:30Z"],["dc.date.issued","2016"],["dc.identifier.isi","000383869504532"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39868"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press"],["dc.publisher.place","Oxford"],["dc.relation.conference","Congress of the European-Society-of-Cardiology (ESC)"],["dc.relation.eventlocation","Rome, ITALY"],["dc.relation.issn","1522-9645"],["dc.relation.issn","0195-668X"],["dc.title","Impact of acute and chronic renal injury in patients undergoing MitraClip implantation: retrospective data analysis from two German high-volume centers"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","58"],["dc.bibliographiccitation.journal","International Journal of Cardiology"],["dc.bibliographiccitation.lastpage","63"],["dc.bibliographiccitation.volume","234"],["dc.contributor.author","Hellenkamp, Kristian"],["dc.contributor.author","Becker, Alexander"],["dc.contributor.author","Gabriel, Yannick D."],["dc.contributor.author","Hasenfuss, Gerd"],["dc.contributor.author","Hünlich, Mark"],["dc.contributor.author","Jacobshagen, Claudius"],["dc.contributor.author","Schillinger, Wolfgang"],["dc.contributor.author","Schroeter, Marco R."],["dc.date.accessioned","2018-04-23T11:48:16Z"],["dc.date.available","2018-04-23T11:48:16Z"],["dc.date.issued","2017"],["dc.description.abstract","Background Bioresorbable vascular scaffolds (BVS) are widely used in routine clinical practice. While previous studies reported acceptable short- to midterm outcome after BVS implantation, data on longer-term outcome are rare. Methods Patients treated with at least one Absorb®-BVS were consecutively enrolled. Follow-up data were assessed after 834.0 [769.0–1026.0] days. The primary device-oriented composite endpoint (DOCE) was defined as cardiovascular death, myocardial infarction (MI) and/or target lesion revascularization (TLR). Results Between 2012 and 2014, 195 patients were included into study analysis. Overall, 244 BVS were implanted. Mean patient age was 64.0[54.3–74.0] years. Three-quarter of patients had an ACS; of those 42.9% had ST-elevation-MI and 40.8% had non-ST-elevation-MI. DOCE occurred in 3.1%, 6.7%, 11.8% and 15.4% of patients during hospital stay, within 6-months, 18-months or during the complete follow-up period, respectively. In those patients, median time until DOCE was 211.5[43.25–567.25] days. In 11 (36.7%) patients DOCE occurred after > 12 months. Using univariable analysis, bifurcation stenting was associated with a hazard ratio (HR) of 11.8[2.38–58.57] for TLR (p = 0.002) and 2.1[1.02–4.49] for DOCE (p = 0.045). Similarly, in ACS patients, bifurcation stenting was associated with an increased risk for TLR (HR = 10.4[2.01–53.56]; p = 0.005) and for DOCE (HR = 2.4[1.09–5.32]; p = 0.029) and in multivariable analysis, it remained an independent predictor of DOCE (HR = 3.0; p = 0.018). Conclusions Although, the rates of (potentially) device-related complications following BVS implantation are acceptable, they are nonetheless not negligible. Interestingly, they did not decline over time. Bifurcation stenting could be found as relevant procedure-related predictor of DOCE, especially in ACS patients. Randomized trials are warranted to confirm these findings."],["dc.identifier.doi","10.1016/j.ijcard.2017.02.069"],["dc.identifier.gro","3142343"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/13479"],["dc.language.iso","en"],["dc.notes.intern","lifescience updates Crossref Import"],["dc.notes.status","final"],["dc.relation.issn","0167-5273"],["dc.title","Mid- to long-term outcome of patients treated with everolimus-eluting bioresorbable vascular scaffolds: Data of the BVS registry Göttingen predominantly from ACS patients"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","391"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Clinical Research in Cardiology"],["dc.bibliographiccitation.lastpage","399"],["dc.bibliographiccitation.volume","98"],["dc.contributor.author","Schillinger, Wolfgang"],["dc.contributor.author","Hoernes, Nina"],["dc.contributor.author","Teucher, Nils"],["dc.contributor.author","Sossalla, Samuel"],["dc.contributor.author","Sehrt, Daniel"],["dc.contributor.author","Jung, Klaus"],["dc.contributor.author","Huenlich, Mark"],["dc.contributor.author","Unsoeld, Bernhard W."],["dc.contributor.author","Geiling, Bianca"],["dc.contributor.author","Ramadori, Giuliano"],["dc.contributor.author","Hilgers, Reinhard"],["dc.contributor.author","Schwoerer, Harald"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.date.accessioned","2017-09-07T11:47:26Z"],["dc.date.available","2017-09-07T11:47:26Z"],["dc.date.issued","2009"],["dc.description.abstract","Reports on cardiac problems with oral proton pump inhibitors have caused extensive safety reviews by the US Food and Drug Administration. We provide additional data on acute cardiac effects of an intravenous application. Echocardiography was performed in 18 healthy volunteers after administration of a common high-dose regimen of pantoprazole (80 mg i.v. bolus followed by 8 mg/h for 1 h) or placebo. The design included a randomized, double-blind, placebo-controlled cross-over trial. Ejection fraction (%, mean +/- A SE) in the treatment group (placebo group) was 60.7 +/- A 1.1 (61.2 +/- A 1.7) at baseline, and 62.6 +/- A 1.1 (62.1 +/- A 1.9), 64.7 +/- A 1.6 (63.5 +/- A 1.3), 62.6 +/- A 1.6 (61.0 +/- A 1.6) and 63.0 +/- A 1.4 (61.8 +/- A 1.5) at 7.5, 15, 30 and 60 min after bolus application, respectively (p = n.s.). Similarly, no significant changes were found for cardiac output, cardiac index, blood pressure and heart rate. In contrast, gastric pH that was used as a treatment control was significantly increased 60 min after the application of pantoprazole as compared to baseline and to placebo. Pantoprazole as injection is safe in healthy subjects with respect to cardiac contractile function. However, in view of recent reports of negative inotropy of the drug, further studies in heart failure patients are required."],["dc.identifier.doi","10.1007/s00392-009-0012-6"],["dc.identifier.gro","3143105"],["dc.identifier.isi","000267217400008"],["dc.identifier.pmid","19301059"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?goescholar/3460"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/583"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Dr Dietrich Steinkopff Verlag"],["dc.relation.issn","1861-0684"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Recent in vitro findings of negative inotropy of pantoprazole did not translate into clinically relevant effects on left ventricular function in healthy volunteers"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]